脑生物标记市场报告：2031 年趋势、预测与竞争分析

全球脑生物标记市场前景光明，医院、研究实验室、门诊手术中心和诊断实验室市场都存在机会。预计到 2031 年，全球脑生物标记市场规模将达到 180 亿美元，2025 年至 2031 年的复合年增长率为 7.4%。该市场的主要驱动力是对神经系统疾病精准诊断技术的需求不断增长，对有助于早期发现和管理心理健康问题的生物标誌物的需求不断增长，以及对个性化医疗的需求不断增长，其中脑生物标誌物可用于为神经系统疾病患者制定个性化治疗计划。

• 根据产品类型，Lucintel 预测生物标记检测套组在预测期内仍将占据很大份额，因为它们在诊断和研究中发挥关键作用，为识别和量化与各种神经系统疾病相关的生物标记提供了可靠有效的技术。
• 根据最终用途，生物标记将继续成为最大的细分市场，因为医院将其用于各种目的，例如早期疾病识别和治疗监测，从而实现及时干预和客製化治疗方法。
• 根据地区，预计北美在预测期内仍将是最大的地区。

脑生物标誌物市场的策略性成长机会

由于研究和技术的进步以及神经系统疾病盛行率的上升，脑生物标记市场正在出现多种策略性成长机会。

• 阿兹海默症的早期诊断：对阿兹海默症早期诊断工具的需求正在创造巨大的成长机会。生物标记有助于早期诊断，从而及时介入并改善患者的治疗效果。
• 推进治疗选择：向个人化医疗的转变为生物标记指导治疗铺平了道路。根据特定的生物标记谱开发治疗方法可以实现更有效、更有针对性的治疗，同时降低副作用的风险。
• 投资神经退化性疾病研究：人们对帕金森氏症和多发性硬化症等疾病的兴趣日益浓厚，推动了对脑生物标记研究的投资。在这些领域发现的新生物标记可以帮助更有效地诊断和监测这些疾病。
• 研究合作：学术界、研究机构和产业相关人员之间加强合作正在加速生物标记的发现和应用。这样的伙伴关係有助于缩短研究时间并更快地将新的诊断工具推向市场。
• 扩大临床应用：在临床实践中应用生物标记的需求日益增加。随着生物标记被检验具有更广泛的用途，它们在各种神经系统疾病的诊断和管理中应用的机会可能会增加。

这些机会凸显了脑生物标记市场持续成长的潜力，为神经病学领域的新发现和加强患者照护提供了途径。

脑生物标记市场驱动因素与挑战

脑生物标记产品的商业化受到许多驱动因素和挑战的影响，包括现有技术、社会经济和法规环境。为了在市场中运营，了解这些动态非常重要。

推动脑生物标记市场发展的因素有：

• 技术进步：生物标记检测及其分析的原理、方法和手段的持续技术改进确保了市场的成长。新的识别技术和诊断技术、基因组学和蛋白​​质组学技术的发展将提高诊断的敏感性和特异性。
• 增加研究经费：分配给神经科学和神经系统疾病研究的投资不断增加，推动了脑生物标记的成长。临床试验资金筹措通常相当可观，津贴和促进可带来有效决策的检验过程。
• 神经系统疾病发生率上升：阿兹海默症和帕金森氏症新患者不断增加，需要有效的诊断解决方案。在这些情况下，生物标记可以帮助临床检测和监测病情。
• 基于生物标记的检测需求不断增加：个人化医疗的兴起带来了基于生物标记的诊断需求。肿瘤学作为临床实践受益于生物标记，因为针对特定患者需求量身定制的治疗方法可以改善临床结果。
• 津贴申请的合作支援：透过与学术界、工业界和临床合作伙伴的有效合作，并行发明支持脑生物标记开发工作。这种合作促进了资源共用并有助于加快进展。

脑生物标记市场面临的挑战是：

• 监管障碍：获得基于生物标誌物的诊断设备的核准既费时又昂贵。漫长的核准过程可能会延迟向需要的患者提供新的诊断工具。
• 财务障碍：开发和检验脑生物标记的成本很高，这带来了挑战，尤其是对于资金有限的小公司。这可能会减缓进展并限制获得创新解决方案的机会。
• 市场竞争：随着越来越多的公司进入脑生物标记市场，竞争日益激烈。为了保持竞争力并获得市场占有率，企业必须使其产品和服务与众不同。

克服市场驱动因素和挑战将是脑生物标记领域成功的关键。

每个新兴国家都在为脑生物标记的发展做出重大贡献，致力于提高神经系统疾病的诊断准确性和治疗性介入。

目录

第一章执行摘要

第二章全球脑生物标记市场：市场动态

• 简介、背景和分类
• 供应链
• 产业驱动力与挑战

第三章 2019年至2031年市场趋势及预测分析

• 宏观经济趋势（2019-2024）及预测（2025-2031）
• 全球脑生物标记市场趋势（2019-2024）及预测（2025-2031）
• 全球脑生物标记市场（依产品类型）
  • 生物标记检测套组
  • 生物标记分析装置
• 全球脑生物标记市场（按疾病适应症）
  • 中风
  • 肌萎缩侧索硬化症和肌萎缩侧索硬化症
  • 阿兹海默症和其他失智症
  • 帕金森氏症
  • 亨丁顿舞蹈症
• 按应用：全球脑生物标记市场
  • 诊断
  • 药物研发
  • 其他的
• 全球脑生物标记市场（按最终用途）
  • 医院
  • 研究部门
  • 门诊手术中心
  • 诊断实验室
  • 其他的

第四章2019年至2031年区域市场趋势与预测分析

• 按地区划分：全球脑生物标记市场
• 北美脑生物标记市场
• 欧洲脑生物标记市场
• 亚太脑生物标记市场
• 世界其他地区脑生物标记市场

第五章 竞争分析

• 产品系列分析
• 业务集成
• 波特五力分析

第六章 成长机会与策略分析

• 成长机会分析
  • 全球脑生物标记市场成长机会（按产品类型）
  • 全球脑生物标记市场成长机会（依疾病指征）
  • 全球脑生物标记市场成长机会（按应用）
  • 全球脑生物标记市场成长机会（依最终用途）
  • 全球脑生物标记市场各区域成长机会
• 全球脑生物标记市场的新趋势
• 战略分析
  • 新产品开发
  • 全球脑生物标记市场容量不断扩大
  • 全球脑生物标记市场的合併、收购和合资企业
  • 认证和许可

第七章主要企业简介

• Siemens Healthineers
• Electrical Geodesics
• Lifesign
• Advanced Brain Monitoring
• BrainScope
• GE Healthcare
• Johnson & Johnson
• Natus Medical
• F. Hoffmann-La Roche
• Qiagen

The future of the global brain biomarker market looks promising with opportunities in the hospital, research laboratory, ambulatory surgical center, and diagnostic laboratory markets. The global brain biomarker market is expected to reach an estimated $18 billion by 2031 with a CAGR of 7.4% from 2025 to 2031. The major drivers for this market are the increased need for precise diagnostic techniques in neurological diseases, the rising need for biomarkers to aid in the early identification and management of mental health issues, and the growing demand for personalized medicine, brain biomarkers can be used to develop personalized treatment plans for patients with neurological disorders.

• Lucintel forecasts that, within the product type category, biomarker test kit will remain the larger segment over the forecast period due to their critical role in diagnostics and research, offering a reliable and effective technique to identify and quantify biomarkers linked with diverse neurological disorders.
• Within the end use category, hospitals will remain the largest segment due to hospitals use biomarkers for a variety of objectives, including early illness identification and treatment monitoring, which allows for prompt interventions and tailored care regimens.
• In terms of regions, North America will remain the largest region over the forecast period.

Gain Valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Brain Biomarker Market

The brain biomarker market is undergoing significant transformation driven by technological advancements, research funding, and the growing emphasis on personalized medicine. These trends are reshaping the way neurological disorders are diagnosed, monitored, and treated.

• AI and Machine Learning Integration: Artificial intelligence (AI) and machine learning are revolutionizing the brain biomarker field by analyzing complex datasets more efficiently. These technologies enhance the discovery of new biomarkers and improve the predictive accuracy of existing ones, simplifying diagnosis and treatment plans.
• Personalized Medicine Approach: Personalized medicine is gaining traction in the brain biomarker market, with treatments increasingly tailored to individual biomarker profiles. By leveraging genetic profiling and biomarker analysis, healthcare providers can customize treatments to improve patient outcomes and minimize adverse effects.
• Increased Investment in Research: Growing funding from both public and private sectors is fueling research into neurological diseases, leading to the discovery of new biomarkers. This investment is critical for early detection, more accurate diagnosis, and more effective treatments.
• Collaboration Between Sectors: Enhanced collaboration between academia, industry, and healthcare organizations is accelerating biomarker development. These partnerships facilitate the transfer of knowledge and resources, leading to faster development and implementation of biomarker-based diagnostics and treatments.
• Regulatory Advancements: Regulatory landscapes are evolving, particularly in Western countries, where there is a growing push to incorporate biomarkers into clinical applications. Relaxation of market access barriers is helping to expedite the use of biomarkers in clinical practice.

These trends are significantly impacting the brain biomarker market, improving both the speed and accuracy of diagnosis and leading to more effective therapeutic interventions for neurological diseases.

Recent Developments in the Brain Biomarker Market

Recent advancements in the brain biomarker market are a result of ongoing technological progress and increased research efforts, particularly in the areas of biomarker discovery, validation, and clinical application.

• FDA Approvals for Novel Biomarkers: Recent FDA approvals of blood-based biomarkers for Alzheimer's disease have opened up new avenues for early detection and treatment. These innovations offer the potential for earlier interventions and more targeted therapeutic strategies.
• AI-Based Biomarker Discovery: The integration of AI in the biomarker discovery process is transforming how large datasets, including genetic and neuroimaging data, are analyzed. AI-driven approaches can identify novel biomarkers with higher predictive potential, enabling earlier diagnosis and better treatment outcomes.
• Collaborative Research Ventures: The convergence of academic institutions, biotech companies, and healthcare providers is accelerating the pace of biomarker development. These partnerships are focused on translating biologically validated biomarkers into clinical practice, bringing innovations to market faster.
• Focus on Proteomics and Genomics: Proteomic and genomic technologies are playing a central role in the search for brain biomarkers. These techniques are uncovering potential biomarkers that can be used for the early detection and monitoring of neurodegenerative diseases.
• Improved Imaging Modalities: Advances in imaging technologies, such as positron emission tomography (PET) and magnetic resonance imaging (MRI), are enhancing the sensitivity, specificity, and quantification of cerebral biomarkers. These imaging advancements are crucial for better understanding and diagnosing brain diseases.

These recent developments are propelling the brain biomarker market forward, with improvements in analytical capabilities and clinical applications leading to better diagnostic and therapeutic strategies.

Strategic Growth Opportunities for Brain Biomarker Market

Several strategic growth opportunities are emerging within the brain biomarker market, driven by advances in research, technology, and the rising incidence of neurological disorders.

• Alzheimer's Disease Early Diagnosis: The need for early diagnostic tools for Alzheimer's disease is creating significant growth opportunities. Biomarkers can aid in early diagnosis, allowing for timely intervention and improved patient outcomes.
• Advancing Treatment Options: The shift toward personalized medicine is paving the way for biomarker-based therapies. Developing treatments based on specific biomarker profiles will enable more effective and targeted therapies, reducing the risk of side effects.
• Investments in Neurodegenerative Disease Research: Growing concerns about diseases like Parkinson's and multiple sclerosis are driving investments in brain biomarker research. New biomarkers discovered in these areas will aid in diagnosing and monitoring these conditions more effectively.
• Research Collaborations: Increasing collaboration between academia, research organizations, and industry players is accelerating biomarker discovery and application. These partnerships are helping to shorten research timelines and bring new diagnostic tools to market more quickly.
• Expanding Clinical Applications: There is a growing demand for the integration of biomarkers into clinical practice. As biomarkers are validated for broader use, there will be more opportunities to apply them in the diagnosis and management of various neurological diseases.

These opportunities underscore the potential for continued growth in the brain biomarker market, offering avenues for new discoveries and enhanced patient care in the field of neurology.

Brain Biomarker Market Driver and Challenges

The commercialization of brain biomarker products is influenced by a number of drivers and challenges such as available technology, and socio-economic and regulatory environment. It is important to know these dynamics in order to operate in the market.

The factors responsible for driving the brain biomarker market include:

• Technological Advancements: The constant technological improvement of principles, methods, and means of biomarker detection and their analysis is ensuring market growth. Development of new identifiers and diagnostic imagination, genomic and proteomic technologies improves sensitivity and specificity in diagnosis.
• Increased Research Funding: The growth in the investment allocated for neuroscience and neurological disorder studies is promoting the growth of brain biomarkers. Financing of clinical trials is usually heavy, and this subsidizes and hastens the process of verification leading to effective decision-making.
• Rising Incidence of Neurological Disorders: New cases of Alzheimer's and Parkinson's diseases are on the rise which in turn pushes for effective diagnostic solutions. Biomarkers, in such cases, help in clinical detection as well as monitoring of the condition.
• Increasing Demand For Biomarker Based Tests: The increase in the adoption of personalized medicine has seen biomarker based diagnostics become sought after. Oncology as a clinical practice benefits from biomarkers since treatment approaches are catered to the needs of specific patients improving clinical outcomes.
• Jointly Helping To Apply For The Grant: Parallel inventions through effective collaborations with academic, industrial, and clinical partners are supporting brain biomarkers developmental efforts. These cooperative relationships foster resource sharing which helps in speeding up progress.

Challenges in the brain biomarker market are:

• Regulatory Barriers: Obtaining regulatory approval for biomarker-based diagnostic devices can be time-consuming and costly. Slow approval processes can delay the availability of new diagnostic tools to patients in need.
• Financial Barriers: The high costs associated with the development and validation of brain biomarkers pose a challenge, particularly for smaller companies with limited financial resources. This can slow down progress and limit access to innovative solutions.
• Market Competition: The growing number of companies entering the brain biomarker market is intensifying competition. Companies must differentiate their products and services to maintain a competitive edge and capture market share.

Navigating these challenges while capitalizing on market drivers will be key to the success of companies in the brain biomarker space.

List of Brain Biomarker Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies brain biomarker companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the brain biomarker companies profiled in this report include-

• Siemens Healthineers
• Electrical Geodesics
• Lifesign
• Advanced Brain Monitoring
• BrainScope
• GE Healthcare
• Johnson & Johnson
• Natus Medical
• F. Hoffmann-La Roche
• Qiagen

Brain Biomarker by Segment

The study includes a forecast for the global brain biomarker market by product type, disease indication, application, end use, and region.

Brain Biomarker Market by Product Type [Analysis by Value from 2019 to 2031]:

• Biomarker Test Kits
• Biomarker Analyzers

Brain Biomarker Market by Disease Indication [Analysis by Value from 2019 to 2031]:

• Stroke
• MND & ALS
• Alzheimer's Disease & Other Dementias
• Parkinson's Disease
• Huntington's Disease

Brain Biomarker Market by Application [Analysis by Value from 2019 to 2031]:

• Diagnosis
• Drug Discovery and Development
• Others

Brain Biomarker Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Research Laboratories
• Ambulatory Surgical Centers
• Diagnostic Laboratories
• Others

Brain Biomarker Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Brain Biomarker Market

The brain biomarker market is growing globally, with key contributions from countries like the United States, China, Germany, India, and Japan. Each of these countries is making strides in the development of brain biomarkers and their clinical applications.

• United States: The U.S. is leading in brain biomarker research and development, particularly in the area of Alzheimer's disease. Recent FDA approvals for blood-based amyloid-beta biomarkers have paved the way for new diagnostic methods. The use of AI in biomarker analysis is also growing, enhancing diagnostic accuracy and speed.
• China: China is investing heavily in brain biomarker research, particularly for neurodegenerative diseases. Collaborations with international institutions are helping to validate biomarkers, and AI integration is improving data analysis capabilities. Rising mental health awareness is driving demand for more biomarker studies.
• Germany: Germany is at the forefront of brain biomarker development, with advancements in imaging technologies and a strong emphasis on clinical implementation. The country is also promoting deeper collaboration between industries and universities to drive innovation.
• India: India's brain biomarker market is expanding due to increased research activities in neurology and psychiatry. Researchers are focusing on low-cost biomarker discovery, which makes the technology more accessible to the local population. The increasing prevalence of neurological diseases is further driving demand.
• Japan: Japan is a leader in integrating AI technologies into brain biomarker research. The country is also advancing the use of biomarkers in clinical trials for neuro-stimulating drugs, improving patient outcomes and treatment efficacy.

Each of these countries is making significant contributions to the development of brain biomarkers, with a focus on improving diagnostic accuracy and therapeutic interventions for neurological diseases.

Features of the Global Brain Biomarker Market

Market Size Estimates: Brain biomarker market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecasts (2025 to 2031) by various segments and regions.

Segmentation Analysis: Brain biomarker market size by various segments, such as by product type, disease indication, application, end use, and region in terms of value ($B).

Regional Analysis: Brain biomarker market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different product type, disease indication, application, end use, and regions for the brain biomarker market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the brain biomarker market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the brain biomarker market by product type (biomarker test kits and biomarker analyzers), disease indication (stroke, MND & ALS, Alzheimer's disease & other dementias, Parkinson's disease, and Huntington's disease), application (diagnosis, drug discovery and development, and others), end use (hospitals, research laboratories, ambulatory surgical centers, diagnostic laboratories, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Brain Biomarker Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Brain Biomarker Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Brain Biomarker Market by Product Type
  • 3.3.1: Biomarker Test Kits
  • 3.3.2: Biomarker Analyzers
• 3.4: Global Brain Biomarker Market by Disease Indication
  • 3.4.1: Stroke
  • 3.4.2: MND & ALS
  • 3.4.3: Alzheimer's Disease & Other Dementias
  • 3.4.4: Parkinson's Disease
  • 3.4.5: Huntington's Disease
• 3.5: Global Brain Biomarker Market by Application
  • 3.5.1: Diagnosis
  • 3.5.2: Drug Discovery and Development
  • 3.5.3: Others
• 3.6: Global Brain Biomarker Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Research Laboratories
  • 3.6.3: Ambulatory Surgical Centers
  • 3.6.4: Diagnostic Laboratories
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Brain Biomarker Market by Region
• 4.2: North American Brain Biomarker Market
  • 4.2.1: North American Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.2.2: North American Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.3: European Brain Biomarker Market
  • 4.3.1: European Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.3.2: European Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.4: APAC Brain Biomarker Market
  • 4.4.1: APAC Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.4.2: APAC Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others
• 4.5: ROW Brain Biomarker Market
  • 4.5.1: ROW Market by Product Type: Biomarker Test Kits and Biomarker Analyzers
  • 4.5.2: ROW Market by End Use: Hospitals, Research Laboratories, Ambulatory Surgical Centers, Diagnostic Laboratories, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Brain Biomarker Market by Product Type
  • 6.1.2: Growth Opportunities for the Global Brain Biomarker Market by Disease Indication
  • 6.1.3: Growth Opportunities for the Global Brain Biomarker Market by Application
  • 6.1.4: Growth Opportunities for the Global Brain Biomarker Market by End Use
  • 6.1.5: Growth Opportunities for the Global Brain Biomarker Market by Region
• 6.2: Emerging Trends in the Global Brain Biomarker Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Brain Biomarker Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Brain Biomarker Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: Siemens Healthineers
• 7.2: Electrical Geodesics
• 7.3: Lifesign
• 7.4: Advanced Brain Monitoring
• 7.5: BrainScope
• 7.6: GE Healthcare
• 7.7: Johnson & Johnson
• 7.8: Natus Medical
• 7.9: F. Hoffmann-La Roche
• 7.10: Qiagen